News >

Avelumab Falls Short as Frontline Maintenance for Gastric/GEJ Cancer

Jason M. Broderick @jasoncology
Published: Friday, Nov 08, 2019

Markus Mohler, MD, PhD, head of GI Oncology, senior physician Gastroenterology & Endosonography, Johannes-Gutenberg University, Mainz, Germany

Markus Möhler, MD, PhD

Avelumab (Bavencio) did not improve overall survival (OS) as frontline maintenance following induction chemotherapy in patients with unresectable, locally advanced, or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, according to topline results from the phase III JAVELIN Gastric 100 study.1

Grade ≥3 treatment-related AEs occurred in 9.2% of the avelumab group compared with 31.6% of the chemotherapy group.


  1. EMD Serono and Pfizer provide update on phase III JAVELIN GASTRIC 100 trial. Pfizer. Published November 8, 2019. Accessed November 8, 2019.  
  2. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29(10):2052-2060. doi: 10.1093/annonc/mdy264.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication